Canaccord analyst William Plovanic raised the firm’s price target on Stryker to $360 from $315 and keeps a Buy rating on the shares. The firm said they delivered a strong Q4 in the face of a tough Q4/22 comp, beating on the top and bottom lines and continuing to note healthy capital demand.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
